Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses doubts about the effectiveness of topical finasteride for hair loss, suggesting that DHT could be produced elsewhere in the body and affect the scalp. It proposes that androgen receptor antagonists like spironolactone and clascoterone might be more effective as they could prevent this potential bypass mechanism.

Hair loss discussion involves experimenting with Sulforaphane from broccoli sprouts and possibly procyanidin b2. People seek updates on progress and if it's worth adding to treatment stack like microneedling.

The conversation discusses hair loss treatments, specifically asking about clinics in the US that perform dutasteride mesotherapy. Minoxidil, finasteride, and RU58841 are also mentioned.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

The user's experience with hair loss, their doctor explaining that they were likely hyper aware of thin spots due to anxiety and an underlying whorl in one area, and providing encouragement for those feeling discouraged. Treatments mentioned include minoxidil and spironolactone.

Hair follicle cloning is claimed to be possible but not widely available due to potential safety issues, such as cancer risks. Current treatments like finasteride and dutasteride are not effective for everyone, and there is frustration over limited access to these medications.

User seeks reputable international finasteride seller due to dermatologists refusing prescription. Dermatologists suggested PRP or exosomes instead.

The user reports promising hair regrowth without using finasteride, focusing instead on microneedling, dermarolling, minoxidil, tretinoin, scalp massages, and red light therapy. They emphasize consistency and a healthier, side-effect-free approach.

New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.

The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.

A user experienced an allergic reaction, including swollen lymph nodes, to Minoxidil 5% with an aqueous base. Switching to a non-alcohol-based Minoxidil (Prolox 5%) resolved the allergies.

A 21-year-old noticed vellus hair regrowth on their hairline after adopting a healthy lifestyle and meditation, without using treatments like Minoxidil or Finasteride. Other users are skeptical, attributing the regrowth to placebo effects.

A 16-year-old researching and trying Pyrilutamide for hair loss treatment, reporting back on side effects experienced after one week of use; the reported side effects included testicle pain, headache, and increased shedding. Libido and sexual performance seemed unaffected.

Minoxidil and spironolactone are used for hair regrowth, with visible progress noted. Spironolactone is discussed as a treatment option, particularly in the context of transitioning, with concerns about its effects on men.

The user has been using topical minoxidil and finasteride for four months, along with microneedling and Nizoral, noticing thicker lashes and eyebrows but not much scalp hair growth. They apply the treatment twice daily with a 5% minoxidil and 0.3% finasteride solution.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

A questionable paper which suggests that 5% topical spironolactone is more effective than 0.1% topical finasteride for treating hair loss. It should be taken with a grain of salt due to the journal it was published in.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

The user has been using Minoxidil for 2 months and Finasteride for 1 month to address hair loss, particularly at the temples. They are questioning whether the new small hairs are facial hairs or new scalp hair.

Hair loss discussion mentions Verterporfin for scar-free healing and hair follicle regeneration. Human study expected within 2 years.

A user shared their experience with DIY PRP scalp injections for hair regrowth, using an EZ Injector and other at-home equipment. Another user reported success with at-home PRP treatments for 1.5 years, noting thicker hair and a stable hairline.

A 21-year-old woman with female pattern baldness has tried minoxidil, red light therapy, and supplements without success. She is considering spironolactone and seeking medical advice.

A 26 year old female dealing with hair loss who is considering treatments such as Spiro, minoxidil and finasteride. Other potential solutions mentioned are PRP treatment, a wig, and bio-identical estrogen combined with bica.

Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.

A user shared their 12-month progress using 0.5% Pyrilutamide once daily, 0.025% topical finasteride once daily, 5% Minoxidil twice daily, and microneedling 3 times a week. They reported good progress but noted a slowdown in recent months, hoping for thicker hair soon.

A user's progress after 3 months of using the "big 4" hair loss treatments - liposomal gel minoxidil, finasteride, keto shampoo and microneedling; with people providing advice about their own experiences and asking for more information.

Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.

A 29-year-old shared their hair recovery progress using a liposomal topical finasteride/minoxidil solution, LLLT helmet, and vitamins, noting that transplants were only on the hairline. They highlighted the effectiveness of their regimen and addressed skepticism with photos.

Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.

The user experienced no improvement in hair loss with finasteride and minoxidil but had side effects. They plan to add wounding, scalp massage, vitamin K, and taurine supplements to their regimen and seek feedback on these additions.